Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


SuppreMol raises €15.7 million in series B financing

This article was originally published in Scrip

Executive Summary

SuppreMol of Germany has closed a €15.7 million series B financing round. The lead investors were MIG and BioMedInvest. Santo Holding and the existing investors Zetacube, KfW Mittelstandsbank, Bayern Kapital and Max-Planck-Gesellschaft also participated. SuppreMol is developing novel therapeutics for the treatment of autoimmune diseases. The proceeds of the round will be used to advance its lead product SM101, a recombinant human soluble Fc-gamma receptor IIb for the treatment of idiopathic thrombocytopenic purpura (ITP), to clinical proof-of-concept, said the company. SM101, which has been granted orphan drug status in the EU, is scheduled to enter Phase I clinical studies in the first quarter of next year.

You may also be interested in...

UK Reimbursement Decisions Focus Mostly On Cancer

The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.

Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts

While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.

Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer

Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts